
("
Aughrim Exploration Update
Significant Lithium, Tin, Tungsten, and Rare Earths Findings
Key Highlights
· Lithium: analysis revealed anomalous lithium oxide (Li2O) results in rock samples. Notably, up to 0.09% Li2O was detected, with 26 out of 59 samples showing concentrations greater than 0.02% Li2O. Minor spodumene crystals, constituting less than 1% of the total rock mineralogy, were observed in some pegmatite and aplite samples.
· Beryllium and lithium in pegmatite: one pegmatite sample showed a significant concentration of 0.246% beryllium and 0.03% Li2O, indicating the potential presence of economic beryllium in the block.
· Ballinglen tin & tungsten target: results from the Ballinglen area revealed 0.028% tin (Sn) and 0.179% tungsten (W), along with an anomalous lithium presence of 0.08% Li2O.
·
· Gold: anomalous gold grades were detected within the block, with findings of 0.74ppm Au hosted within quartz vein float.
· Rare earth elements: a sample analysis revealed the presence of rare earth elements, including 104ppm cerium (Ce), 27.4ppm dysprosium (Dy), and other significant concentrations. Although not currently economic, the combined rare earths exceeding 0.05% represent an intriguing exploration target.
Next Steps
This announcement has been reviewed and approved by Gavin Berkenheger (CGeol) in his capacity as the Qualified Person for the purposes of the AIM Note for Mining, Oil and Gas Companies issued by the
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of
Enquiries:
|
|
|
+353 (0) 1 833 2833 |
|
+353 (0) 1 833 2833 |
|
|
|
|
|
+44 (0) 203 470 0470 |
|
|
|
|
Joint Broker |
|
|
+44 (0) 207 374 2212 |
|
|
BlytheRay |
+44 (0) 207 138 3204 |
|
|
|
|
Teneo |
|
|
+353 (0) 1 661 4055 |
|
|
|
|
|
|
Information for Editors
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the